高级检索
当前位置: 首页 > 详情页

Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Gastrointestinal Surgery, The First Hospital of Shanxi Medical University, Shanxi, China [2]Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China [3]Department of Gastrosurgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
出处:
ISSN:

关键词: Gastric cancer (GC) human epidermal growth factor receptor 2 amplification microsatellite instability (MSI) tumor mutational burden (TMB) biomarker

摘要:
Gastric cancer (GC) is one of the most common cancers worldwide. However, little is known about the combination of HER2 amplification and microsatellite instability (MSI) status in GC. This study aimed to analyze the correlation of HER2 amplification with microsatellite instability (MSI) status, clinical characteristics, and the tumor mutational burden (TMB) of patients. A total of 192 gastric cancer (GC) patients were enrolled in this cohort. To analyze genomic alterations (GAs), deep sequencing was performed on 450 target cancer genes. TMB was measured by an in-house algorithm. MSI status was inferred based on the MANTIS (Microsatellite Analysis for Normal-Tumor InStability) score. The most frequently amplified genes in the GC patients included cyclin E1 (CCNE1), human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 2 (FGFR2), cyclin D1 (CCND1), fibroblast growth factor 19 (FGF19), fibroblast growth factor 3 (FGF3), and fibroblast growth factor 4 (FGF4). The frequency of HER2 amplification was 9.38% (18/192). HER2 amplification was higher in females than in males (14.52% vs. 6.92%, respectively, P=0.091), however, MSI was higher in males compared to females (7.69% vs. 4.84%, respectively, P=0.46). HER2 amplification was higher in metastatic loci compared to primary lesions (23.08% vs. 8.38%, respectively, P=0.079) and was lower in patients with high TMB (TMB-H) compared to those with low TMB (TMB-L) (4.0% vs. 11.35%, respectively, P=0.12). While the frequency of MSI in metastatic foci was higher than that in primary lesions (15.38% vs. 6.15%, respectively, P=0.48), MSI status was highly associated with TMB-H (20% vs. 0%, respectively, P=3.66×10-7). Furthermore, HER2 amplification was negatively correlated with MSI status in Chinese GC patients. HER2 amplification was negatively correlated with TMB-H and MSI status, and MSI status was significantly associated with TMB-H in Chinese GC patients. These data suggested that HER2 amplification might be a negative indicator for GC immunotherapy. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 4 区 胃肠肝病学 4 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 胃肠肝病学 4 区 肿瘤学
JCR分区:
出版当年[2021]版:
Q4 GASTROENTEROLOGY & HEPATOLOGY Q4 ONCOLOGY
最新[2024]版:
Q3 GASTROENTEROLOGY & HEPATOLOGY Q3 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Department of Gastrointestinal Surgery, The First Hospital of Shanxi Medical University, Shanxi, China
共同第一作者:
通讯作者:
通讯机构: [2]Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, Qingdao, China [3]Department of Gastrosurgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China [*1]Department of Gastrointestinal Surgery, The Affiliated Hospital of Qingdao University, No. 16, Jiangsu Road, Shinan District, Qingdao 260003, China [*2]Department of Gastrosurgery, The Fourth Hospital of Hebei Medical University, No. 12 Jiankang Road, Shijiazhuang 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study [2]Iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors: A single-arm, multicenter, pivotal, phase II study [3]Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial [4]A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors [5]Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study. [6]PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC) [7]Investigation of Inhibition Effect of Gossypol-Acetic Acid on Gastric Cancer Cells Based on a Network Pharmacology Approach and Experimental Validation [8]PD-1/PD-L1在胃癌组织中的表达及其临床意义 [9]Hsa_circ_0002320: a novel clinical biomarker for colorectal cancer prognosis [10]Correlation between microsatellite instability and RAS gene mutation and stage III colorectal cancer

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号